Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Therapeutic Drug Monitoring of Oral Anticancer Drugs: The Dutch Pharmacology Oncology Group-Therapeutic Drug Monitoring Protocol for a Prospective Study.
Groenland SL, van Eerden RAG, Verheijen RB, Koolen SLW, Moes DJAR, Desar IME, Reyners AKL, Gelderblom HJ, van Erp NP, Mathijssen RHJ, Huitema ADR, Steeghs N. Groenland SL, et al. Among authors: van eerden rag, van erp np. Ther Drug Monit. 2019 Oct;41(5):561-567. doi: 10.1097/FTD.0000000000000654. Ther Drug Monit. 2019. PMID: 31568233 Review.
Therapeutic drug monitoring-based precision dosing of oral targeted therapies in oncology: a prospective multicenter study.
Groenland SL, van Eerden RAG, Westerdijk K, Meertens M, Koolen SLW, Moes DJAR, de Vries N, Rosing H, Otten H, Vulink AJE, Desar IME, Imholz ALT, Gelderblom H, van Erp NP, Beijnen JH, Mathijssen RHJ, Huitema ADR, Steeghs N; Dutch Pharmacology Oncology Group (DPOG). Groenland SL, et al. Among authors: van eerden rag. Ann Oncol. 2022 Oct;33(10):1071-1082. doi: 10.1016/j.annonc.2022.06.010. Epub 2022 Jun 28. Ann Oncol. 2022. PMID: 35777707 Free article.
Cost-Neutral Optimization of Pazopanib Exposure by Splitting Intake Moments: A Prospective Pharmacokinetic Study in Cancer Patients.
Groenland SL, van Eerden RAG, Verheijen RB, de Vries N, Thijssen B, Rosing H, Beijnen JH, Koolen SLW, Mathijssen RHJ, Huitema ADR, Steeghs N; Dutch Pharmacology Oncology Group (DPOG). Groenland SL, et al. Among authors: van eerden rag. Clin Pharmacokinet. 2020 Jul;59(7):941-948. doi: 10.1007/s40262-020-00863-5. Clin Pharmacokinet. 2020. PMID: 32020530 Clinical Trial.
Feasibility of therapeutic drug monitoring of sorafenib in patients with liver or thyroid cancer.
Guchelaar NAD, van Eerden RAG, Groenland SL, Doorn LV, Desar IME, Eskens FALM, Steeghs N, van Erp NP, Huitema ADR, Mathijssen RHJ, Koolen SLW; Dutch Pharmacology Oncology Group. Guchelaar NAD, et al. Among authors: van eerden rag. Biomed Pharmacother. 2022 Sep;153:113393. doi: 10.1016/j.biopha.2022.113393. Epub 2022 Jul 11. Biomed Pharmacother. 2022. PMID: 35834987 Free article.
Intratumoral Comparison of Nanoparticle Entrapped Docetaxel (CPC634) with Conventional Docetaxel in Patients with Solid Tumors.
Atrafi F, van Eerden RAG, van Hylckama Vlieg MAM, Oomen-de Hoop E, de Bruijn P, Lolkema MP, Moelker A, Rijcken CJ, Hanssen R, Sparreboom A, Eskens FALM, Mathijssen RHJ, Koolen SLW. Atrafi F, et al. Among authors: van eerden rag, van hylckama vlieg mam. Clin Cancer Res. 2020 Jul 15;26(14):3537-3545. doi: 10.1158/1078-0432.CCR-20-0008. Epub 2020 Apr 22. Clin Cancer Res. 2020. PMID: 32321718 Clinical Trial.
Effects of Protein and Calorie Restriction on the Metabolism and Toxicity Profile of Irinotecan in Cancer Patients.
de Man FM, van Eerden RAG, van Doorn GM, Oomen-de Hoop E, Koolen SLW, Olieman JF, de Bruijn P, Veraart JN, van Halteren HK, Sandberg Y, Moelker A, IJzermans JNM, Lolkema MP, van Gelder T, Dollé MET, de Bruin RWF, Mathijssen RHJ. de Man FM, et al. Among authors: van doorn gm, van eerden rag, van gelder t, van halteren hk. Clin Pharmacol Ther. 2021 May;109(5):1304-1313. doi: 10.1002/cpt.2094. Epub 2020 Dec 6. Clin Pharmacol Ther. 2021. PMID: 33119892 Clinical Trial.
Concomitant intraperitoneal and systemic chemotherapy for extensive peritoneal metastases of colorectal origin: protocol of the multicentre, open-label, phase I, dose-escalation INTERACT trial.
de Boer NL, Brandt-Kerkhof ARM, Madsen EVE, Diepeveen M, van Meerten E, van Eerden RAG, de Man FM, Bouamar R, Koolen SLW, de Hingh IHJT, Bakkers C, Rovers KP, Creemers GM, Deenen MJ, Kranenburg OW, Constantinides A, Mathijssen RHJ, Verhoef C, Burger JWA; Dutch Peritoneal Oncology Group (DPOG); Dutch Colorectal Cancer Group (DCCG). de Boer NL, et al. Among authors: van meerten e, van eerden rag. BMJ Open. 2019 Dec 8;9(12):e034508. doi: 10.1136/bmjopen-2019-034508. BMJ Open. 2019. PMID: 31818845 Free PMC article.
16 results